Overall Status

Completed (45)

Terminated (12)

Recruiting (7)

Active, not recruiting (5)

Withdrawn (4)

Unknown status (3)

Not yet recruiting (2)

No longer available (1)

Phase

phase 2 (29)

phase 1 (14)

phase 3 (14)

phase 4 (9)

phase 1/phase 2 (6)

n/a (3)

early phase 1 (1)

phase 2/phase 3 (1)

Study Documents

Intervention Type

drug (77)

other (5)

biological (4)

procedure (3)

behavioral (2)

radiation (2)

dietary supplement (1)

Funder Type

Industry (45)

Other (32)

NIH (2)

Study Type

Interventional (77)

Expanded Access (1)

Observational (1)

AMN107

Showing 76 - 79 of 79

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Myelogenous Leukemia Trial in Worldwide (Imatinib, Nilotinib (AMN107))

Terminated

Has Results

Myelogenous Leukemia

Imatinib
Nilotinib (AMN107)

Tucson, Arizona
+79 more

Nov 4, 2011

Acute Myelogenous Leukemia, Agnogenic Myeloid Metaplasia, Chronic Myelogenous Leukemia Trial in Houston (Imatinib Mesylate

Completed

Acute Myelogenous Leukemia
+2 more

Imatinib Mesylate (Gleevec)
PTK 787 (vatalanib)

Houston, Texas

M.D. Anderson Cancer Center

Jan 19, 2012

Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in Houston (Interleukin-11 (IL-11 or Neumega))

Completed

Has Results

Leukemia
+2 more

Interleukin-11 (IL-11 or Neumega)

Houston, Texas

UT MD Anderson Cancer Center

Feb 17, 2012

Healthy Trial (Nilotinib)

Completed

Healthy

Nilotinib

(no location specified)

Mar 18, 2010